Skip to main content

Table 1 Characteristics of Patients Comparing Pembrolizumab plus Chemotherapy or Pembrolizumab alone with Chemotherapy in Included Trials

From: First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Source Histology Therapeutic regimen Chemotherapy Drug No. of patients NO. of response PFSa(m) HR for PFS OSa(m) HR for OS Median Follow-up time (m)
Pem/Pem + Chemo Chemo Pem/Pem + Chemo Chemo
KEYNOTE-021
2016, 2018
nonsquamous Pem + Chemo vs. Chemo AC
1) carboplatin (5 mg/ml/min Q3W)
2) pemetrexed (500 mg/m^2 Q3W)
20 17 16 6 NR NR NR NR 23.9
KEYNOTE-189
2018
nonsquamous Pem + Chemo vs. Chemo AP or AC
1) cisplatin (75 mg/m^2 Q3W) or carboplatin (6 mg/ml/min Q3W)
2) pemetrexed (500 mg/m^2 Q3W)
132 70 81 16 NR 0.36 (0.25–0.52) NR 0.42 (0.26–0.68) 10.5
KEYNOTE-407
2018
squamous Pem + Chemo vs. Chemo PC
1) carboplatin (6 mg/ml/min Q3W)
2) paclitaxel(200 mg/m^2 Q3W) or nab-paclitaxel (100 mg/m^2 Q1W)
73 73 44 24 8.0 vs. 4.2 0.37 (0.24–0.58) NR 0.64 (0.37–1.10) 7.8
KEYNOTE-024
2016, 2017
suqamous and nonsquamous Pem vs. Chemo AP or AC or PC or GP or GC
1) cisplatin (75 mg/m^2 Q3W) or carboplatin (5-6 mg/ml/min Q3W)
2) pemetrexed (500 mg/m^2 Q3W) or paclitaxel (200 mg/m^2 Q3W) or Gemicitabine (1250 mg/m2 d1,8 of Q3W)
154 151 70 45 10.3 vs. 6.0 0.50 (0.37–0.68) 30.0 vs. 14.2 0.63 (0.47–0.86) 25.2
KEYNOTE-042
2018
suqamous and nonsquamous Pem vs. Chemo AC or PC
1) carboplatin (5-6 mg/ml/min Q3W)
2) pemetrexed (500 mg/m^2 Q3W) or paclitaxel (200 mg/m^2 Q3W)
299 300 118 96 7.1 vs. 6.4 0.81 (0.67–0.99) 20.0 vs. 12.2 0.69 (0.56–0.85) 12.8
  1. aData presented as “Pem/Pem + Chemo vs. Chemo”
  2. Abbreviation: Pem Pembrolizumab, Chemo Chemotherapy, NR Not Reported, HR Hazard Ratio, PFS Progression-free Survival, OS Overall survival;